Share

We Must Outsmart Epidemics

century ago, Johnson & Johnson played a leading role in helping to limit the impact of the 1918 Spanish Flu, one of the deadliest pandemics in modern history, by introducing the epidemic mask, made from sterile gauze. It proved so effective that it was also used in later outbreaks.

Humanity remains vulnerable to pandemics, particularly in the age of globalization. But advances in science and new global partnerships have the potential to ensure that we stay one step ahead of these infectious disease health threats.

The biggest lesson we have learned: It is a question of when—not if—the next one strikes. So we have to be ready.

Johnson & Johnson is one of the world's only major healthcare companies actively engaged to prepare, and prevent, a broad range of pandemic threats. Explore just a few of the ways we are working with partners to outsmart epidemics around the globe.

Infectious diseases with pandemic potential need to be proactively addressed—in advance of outbreaks occurring—and developing new vaccines is a central part of any preparedness strategy.

Working together, we can develop the tools to secure and advance human health, bolster economies and give the world reason to truly celebrate our humanity and our ingenuity.

  • expand

  • In collaboration with a large consortium we maintain a stockpile of 1.5 million investigational preventive Ebola vaccines and are working toward licensure.
  • We developed the first new TB medicine in more than 40 years to tackle drug-resistant TB and recently made a 10-year commitment to develop and deliver new innovations.
  • In partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford, we are developing a vaccine against MERS-CoV and advancing novel vaccines against the Lassa and Nipah viruses.
  • In collaboration with BARDA we are developing a portfolio of vaccines and therapeutics to protect communities in the event of an influenza pandemic.
  • We founded the PSRT to bring the full capabilities of the private sector to tackle pandemic threats through the Global Health Security Agenda.

If we are going to successfully protect vulnerable communities from the threat of infectious diseases outbreaks we must collaborate and leverage the very best expertise from across the private and public sectors. At Johnson & Johnson we have always believed in a comprehensive approach to tackling infectious diseases—creating new medicines and healthcare products, helping to spearhead public education efforts, and investing in ongoing education for healthcare workers on the front lines. Our effort to support pandemic preparedness is just the latest example of our company-wide commitment to promote—and protect—health and well-being.

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue